LTRN earnings date and last-quarter result: next report 2026-08-12, last quarter beat, P/E -1.96. Updated 2026-07-23.
Lantern Pharma (LTRN) Research Hub
Lantern Pharma (LTRN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.6238 USD (-1.83%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.96, market cap 0.04B. This hub links to the full technical, earnings and options research available for LTRN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.6238 USD (-1.83%) |
| 52-week range | 0.591 USD – 4.2 USD |
| Trend regime | Range |
| 14-day RSI | 10.7 (Oversold) |
| Trailing P/E | -1.96 |
| Market cap | 0.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for LTRN
Covered Call on LTRN: how it works, illustrative setup around the real 0.6238 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LTRN: how it works, illustrative setup around the real 0.6238 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LTRN: how it works, illustrative setup around the real 0.6238 USD price, max profit/loss, breakeven and when to use it. Educational.
LTRN technical analysis: range, last 0.6238 USD, RSI 10.7, 52w range 0.591 USD–4.2 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LTRN in?
Lantern Pharma (LTRN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LTRN in an uptrend or downtrend?
As of 2026-10-26, LTRN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LTRN's trailing P/E ratio?
LTRN's trailing P/E is -1.96, with a market cap of 0.04B. See the earnings research page for full valuation detail.
When does LTRN next report earnings?
LTRN is next scheduled to report earnings on 2026-08-12.